Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels, producing local anesthesia. Phenylephrine activates α1‑adrenergic receptors, contracting the dilator pupillae muscle to enlarge the pupil. Tropicamide blocks muscarinic receptors, preventing sphincter pupillae contraction, which further enhances mydriasis. Together they give fast, sustained dilation and analgesia.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific surgical procedure and patient factors. It is supplied as a ready‑to‑use intracameral solution, and the prescriber decides the volume to inject.

Safety data for Mydrane in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Mydrane combines three active ingredients in a single intracameral injection, offering simultaneous anesthesia and mydriasis. Compared with separate administrations of lidocaine and phenylephrine or tropicamide, Mydrane simplifies the procedure, reduces injection time, and provides consistent pupil dilation, though individual component selection may be preferred in certain clinical scenarios.

Mydrane should be stored at room temperature, below 25 °C, in its original sealed container. Protect the vial from direct light and moisture. Do not freeze. Inspect the solution for clarity before use and discard if any particles or discoloration are observed.

Mydrane is administered by a trained ophthalmic surgeon as an intracameral injection into the anterior chamber at the start of the procedure. The sterile vial is opened in a controlled environment, and the prescribed volume is injected using a fine‑gauge cannula.

Serious risks include severe allergic reactions (anaphylaxis), sustained elevation of intraocular pressure, persistent mydriasis, corneal endothelial toxicity, and intraocular infection (endophthalmitis). Prompt recognition and management of these events are essential.

Mydrane should be avoided in patients with known hypersensitivity to lidocaine, phenylephrine, or tropicamide, in those with uncontrolled narrow‑angle glaucoma, and in individuals where systemic absorption of phenylephrine could exacerbate cardiovascular disease. The prescribing clinician must assess suitability for each patient.